Insiders Trades
Pharmanutra Stock: price and insider trades · Italy
Pharmanutra: what insiders have been doing
This page follows insider dealings at Pharmanutra as filed with Consob, a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 3 insiders published 3 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
There has been no open-market purchase by an insider of Pharmanutra for at least a year. The median gap between trade and publication is zero days: most filings appear on the same day. The legal deadline for notifying a trade is three business days (MAR article 19).
Compared with its exchange (224 companies, median 3 filings), a count of 3 filings is typical.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by Consob and describes the past, not future prices; it is not investment advice.
Insider Decl.
61
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 7,108 of 24,148 companies
61.9
score / 100
Value39
Quality85
FCF yld2.1%
Earn yld2.5%
EV/EBITDA23.5x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€82.00
Analyst consensus
3 analysts€76.00Target €81.33(-1%)€86.00
Income statement
Revenue€132.9M
Gross profit€102.9M77% margin
EBITDA€34.3M26% margin
Net income€20.0M15.1% margin
Valuation
PER (trailing)37.3x
PER (forward)26.8x
P/Book10.6x
Beta0.17
Balance sheet & cash
Market cap€785.2M
Total debt€20.5M
Free Cash Flow€16.4M
Debt / Equity26%
Profitability & ownership
ROE30.1%
ROA15.2%
% insiders65.0%
% institutions16.3%
Last declaration on 13 May 2026
Declarations61 total
25 of 61 declarations
About Pharmanutra
PharmaNutra is an Italian listed healthcare company traded on Borsa Italiana (FTSE MIB) in Italy, focused on the research, development and commercialization of high-science food supplements and medical devices. The company was founded in 2003 in Pisa by brothers Andrea and Roberto Lacorte, and it has built its identity around innovation, proprietary know-how and a science-led approach to consumer and professional health products. Its headquarters are in Pisa, Via Campodavela 1, anchoring the group in a well-known Italian industrial and pharmaceutical cluster. ([pharmanutra.it](https://www.pharmanutra.it/en/company/))
PharmaNutra’s business model covers the full value chain, from research and formulation to regulatory registration and commercialization. Rather than competing primarily on price, the group emphasizes intellectual property, clinical evidence and proprietary ingredients. The company highlights 22 proprietary raw materials, 25 registered patents, 55 registered trademarks and 191 clinical and basic research studies, which underscores the depth of its scientific positioning and the defensibility of its product platform. ([pharmanutragroup.com](https://pharmanutragroup.com/en/))
Read moreShow less
In operational terms, PharmaNutra is best known for products and platforms linked to iron deficiency, minerals, vitamins, muscle and joint health, and broader nutraceutical applications. Its flagship brand family includes SiderAL®, which is built on the company’s Sucrosomial® Technology, a core differentiator in iron-based supplementation. The group also operates in adjacent health categories and expanded its scientific capabilities with the 2022 acquisition of Akern S.r.l., a company specializing in bioelectrical impedance analysis. That acquisition broadened the group’s offering and reinforced its medical-scientific profile. ([pharmanutragroup.com](https://pharmanutragroup.com/en/history/))
From a competitive perspective, PharmaNutra holds a strong niche position in Italy’s nutraceutical and specialty healthcare market. It combines an Italian heritage and “Made in Italy” brand appeal with a global commercialization footprint. According to the company, it operates in more than 80 countries worldwide, supported by foreign subsidiaries including PharmaNutra U.S.A. Corp. and PharmaNutra España. This international expansion is important because it reduces reliance on the domestic market and gives the company exposure to larger healthcare and consumer-health opportunities abroad. ([pharmanutragroup.com](https://pharmanutragroup.com/en/))
Recent news flow has been constructive. PharmaNutra published its 2024 annual report, continued advancing its international development strategy, and in 2026 announced FDA registration for its Pisa manufacturing facility. That FDA registration is strategically relevant because it strengthens the company’s regulatory standing and manufacturing setup for the U.S. market, enabling internal management of patented blends intended for American distribution. For equity investors, PharmaNutra therefore looks like a specialized healthcare platform with a defensible product base, international growth optionality and a relatively disciplined operating model on Borsa Italiana (FTSE MIB) in Italy. ([pharmanutragroup.com](https://pharmanutragroup.com/wp-content/uploads/2025/04/ANNUAL-FINANCIAL-REPORT-2024_ENG.pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
